Researchers still need to learn which adults with persistent acne benefit most from spironolactone, metformin, and bicalutamide, and what dose and duration work best. A 2026 review positions these repurposed systemics as options beyond isotretinoin, but calls for better patient selection and safety data. Persistent acne means facial breakouts that continue past the teen years, often in adult women, and tend to flare with hormonal shifts.
According to Dermatology Times, the 2026 review describes a shift beyond isotretinoin toward drugs like spironolactone and metabolic agents. Isotretinoin remains most effective for severe acne but carries safety and monitoring burdens. The open questions are practical: who to treat, how to dose, and how to monitor.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why is spironolactone a leading antibiotic alternative?
- Who is metformin really for?
- Why does bicalutamide need more study?
- What can you discuss at your next visit?
Why is spironolactone a leading antibiotic alternative?
Spironolactone blocks androgen signals. Androgens are male-type hormones that increase skin oil and drive breakouts in sensitive adults. The drug is used off-label for persistent and late-onset acne in adult females. The SAFA trial tested this approach in 410 adult women with persistent facial acne.
According to the NIHR Journals Library team, women assigned to spironolactone had greater symptom improvement at 12 weeks, with a wider gap at 24 weeks. The trial paired pills with topical therapy and supports spironolactone as an antibiotic alternative. What remains unclear is long-term management. According to SkinTherapyLetter, typical use is 50-200 mg daily, with slow onset over about 3 months. Acne often returns months after stopping, so many users need extended treatment.
Who is metformin really for?
Metformin improves insulin sensitivity. Better sensitivity can lower IGF-1, a growth signal that raises oil, and calm ovarian androgen signaling by about 20-25%. The 2026 review therefore proposes metabolic phenotyping, meaning blood and symptom checks for insulin resistance or polycystic ovary syndrome, to select therapy. The acne results are mixed. A 188-patient study in polycystic ovary syndrome found acne improved regardless of baseline insulin resistance or body mass.
Other randomized trials found no clear change in acne or excess hair growth. That split leaves the ideal candidate and treatment length unresolved. For readers, the pattern matters more than weight alone. Irregular periods, excess chin hair, oily scalp, and sugar-handling problems point toward a metabolic driver. Normal cycles with jawline flares point more toward direct androgen blockade.
Why does bicalutamide need more study?
Bicalutamide is a selective androgen-receptor blocker. It prevents androgens from switching on oil glands and hair follicles. In premenopausal women, reports describe 10-50 mg daily as active against oily skin, acne, and excess hair, but reviewers say dosing and safety need more proof. The safety stakes are higher than for the other two options.
According to FDA labeling, rare severe liver injury has caused death or hospitalization, and about 1% stopped treatment for hepatitis or marked enzyme rises. The label also warns of fetal harm risk. That profile shapes what research must answer next. Studies need to define the lowest effective acne dose, who needs frequent liver checks, and how to ensure pregnancy prevention during off-label use. Until then, it remains a specialist option, not a first switch.
What can you discuss at your next visit?
Start with your acne history and hormone clues. Note age of onset, cycle pattern, recent weight change, chin hair, hair shedding, and past antibiotics or retinoids. Bring photos of flares and a list of current topicals. Ask about fit and follow-up rather than a brand name.
Key checks include blood pressure, potassium and kidney risks for spironolactone, glucose and cycle review for metformin, and liver and pregnancy planning for bicalutamide. FDA labeling warns spironolactone can raise potassium, with checks soon after starting and regularly after, and lists high potassium, Addison disease, absent urine, and severe kidney disease as contraindications. Useful questions to carry in: Track oiliness, painful deep bumps, and missed school or work days for 12 to 24 weeks. That record helps your clinician adjust dose, switch class, or refer for hormone care.
- Could my pattern be mainly hormonal, mainly metabolic, or mixed?
- What topical pair makes sense if I try a systemic?
- How long before we judge results, and what signals a stop?
- What labs and birth-control plan do I need before and during treatment?
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: What Researchers Still Need to Learn for Adults With Persistent Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: What Researchers Still Need to Learn for Adults With Persistent Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: What Researchers Still Need to Learn for Adults With Persistent Acne